Excision BioTherapeutics
Gene editing company developing CRISPR-based therapies to cure chronic viral infectious diseases including HIV and hepatitis B by directly excising integrated viral DNA from infected cells.
Notes
Excision BioTherapeutics is a clinical-stage gene editing company based in San Francisco, developing CRISPR-based therapies to cure chronic viral infectious diseases. Unlike traditional antiviral therapies that suppress viral replication, Excision's approach uses CRISPR to directly excise integrated viral DNA from infected cells, potentially achieving a functional cure.
The company's lead program, EBT-101, is the first CRISPR-based therapy to enter clinical trials for HIV. The approach targets multiple sites within the HIV genome to prevent viral escape while removing the integrated provirus from infected cells.
Excision is also developing therapies for hepatitis B virus (HBV) using similar approaches to target and eliminate viral DNA.
Team
- Daniel Dornbusch - CEO
- Kamel Khalili, Ph.D. - Co-founder & Scientific Advisor (Temple University)
Additional Research Findings
- Founded in 2015
- Headquarters: San Francisco, California
- Lead program: EBT-101 for HIV (first CRISPR therapy in HIV clinical trials)
- Multi-target CRISPR approach for viral elimination
- Also developing HBV therapies
- Based on pioneering research from Temple University
- Clinical-stage company
- Aims for functional cure of chronic viral infections
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |